IMPORTANCE: Single-nucleotide polymorphisms (SNPs) associated with the CFH, ARMS2, C3, LIPC, CFB, and C2 genes are associated with age-related macular degeneration (AMD); however, the association of these SNPs with angiographic features of neovascular AMD has been inconsistent in previous studies, and to date, no studies have addressed their association with features on optical coherence tomography. OBJECTIVE: To evaluate the influence of genotype of SNPs previously associated with AMD on the phenotype of neovascular lesions. DESIGN, SETTING, AND PARTICIPANTS: Participants for this cross-sectional study were recruited from the 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), a randomized clinical trial. Eligibility criteria for CATT specified that eyes have choroidal neovascularization and visual acuity between 20/25 and 20/320. A subgroup of 835 patients provided blood samples from July 2010 through September 2011 and were genotyped for the SNPs rs1061170 (CFH), rs10490924 (ARMS2),rs2230199 (C3), rs10468017 (LIPC), rs4151667 (CFB), rs547154 (C2) using TaqMan SNP genotyping assays. Data analysis was initiated in November 2013 and completed in January 2016. MAIN OUTCOMES AND MEASURES: Pretreatment ocular characteristics on fluorescein angiography (lesion type, area of neovascularization and total lesion, retinal angiomatous proliferation) and on time-domain optical coherence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual acuity, and age. RESULTS:A total of 835 (73%) of 1150 CATT patients were genotyped. Mean age decreased with the number of risk alleles for CFH (P < .001), ARMS2 (P < .001), and C3 (P = .005). The following results were found as the number of risk alleles increased from 0 to 1 to 2. For CFH, mean total thickness decreased from 476 to 476 to 434 µm (P = .01; adjusted for age, sex, and smoking status). For ARMS2, the mean area of the total lesion increased from 2.0 to 2.8 to 2.4 mm2 (P = .03), the proportion with retinal angiomatous proliferation lesions increased from 8% to 10% to 12% (P = .05), and the proportion with intraretinal fluid increased from 72% to 71% to 82% (P = .008). For C3, the proportion with intraretinal fluid decreased from 78% to 69% to 64% (P = .001), and the mean retinal thickness decreased from 225 to 207 to 197 µm (P = .02). CONCLUSIONS AND RELEVANCE: CFH, ARMS2, and C3 were associated with specific features of neovascularization at the time patients were enrolled in CATT. Previously identified associations of ARMS2 and CFH with type of choroidal neovascularization on fluorescein angiography were not confirmed. New associations with OCT features identified in CATT need confirmation to establish whether a true association exists. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00593450.
RCT Entities:
IMPORTANCE: Single-nucleotide polymorphisms (SNPs) associated with the CFH, ARMS2, C3, LIPC, CFB, and C2 genes are associated with age-related macular degeneration (AMD); however, the association of these SNPs with angiographic features of neovascular AMD has been inconsistent in previous studies, and to date, no studies have addressed their association with features on optical coherence tomography. OBJECTIVE: To evaluate the influence of genotype of SNPs previously associated with AMD on the phenotype of neovascular lesions. DESIGN, SETTING, AND PARTICIPANTS: Participants for this cross-sectional study were recruited from the 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT), a randomized clinical trial. Eligibility criteria for CATT specified that eyes have choroidal neovascularization and visual acuity between 20/25 and 20/320. A subgroup of 835 patients provided blood samples from July 2010 through September 2011 and were genotyped for the SNPs rs1061170 (CFH), rs10490924 (ARMS2),rs2230199 (C3), rs10468017 (LIPC), rs4151667 (CFB), rs547154 (C2) using TaqMan SNP genotyping assays. Data analysis was initiated in November 2013 and completed in January 2016. MAIN OUTCOMES AND MEASURES: Pretreatment ocular characteristics on fluorescein angiography (lesion type, area of neovascularization and total lesion, retinal angiomatous proliferation) and on time-domain optical coherence tomography (presence of intraretinal, subretinal, and subretinal pigment epithelium fluid; thickness at the foveal center of the retina, subretinal fluid, and subretinal tissue complex), visual acuity, and age. RESULTS: A total of 835 (73%) of 1150 CATT patients were genotyped. Mean age decreased with the number of risk alleles for CFH (P < .001), ARMS2 (P < .001), and C3 (P = .005). The following results were found as the number of risk alleles increased from 0 to 1 to 2. For CFH, mean total thickness decreased from 476 to 476 to 434 µm (P = .01; adjusted for age, sex, and smoking status). For ARMS2, the mean area of the total lesion increased from 2.0 to 2.8 to 2.4 mm2 (P = .03), the proportion with retinal angiomatous proliferation lesions increased from 8% to 10% to 12% (P = .05), and the proportion with intraretinal fluid increased from 72% to 71% to 82% (P = .008). For C3, the proportion with intraretinal fluid decreased from 78% to 69% to 64% (P = .001), and the mean retinal thickness decreased from 225 to 207 to 197 µm (P = .02). CONCLUSIONS AND RELEVANCE: CFH, ARMS2, and C3 were associated with specific features of neovascularization at the time patients were enrolled in CATT. Previously identified associations of ARMS2 and CFH with type of choroidal neovascularization on fluorescein angiography were not confirmed. New associations with OCT features identified in CATT need confirmation to establish whether a true association exists. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00593450.
Authors: Francis Char DeCroos; Cynthia A Toth; Sandra S Stinnett; Cynthia S Heydary; Russell Burns; Glenn J Jaffe Journal: Ophthalmology Date: 2012-08-28 Impact factor: 12.079
Authors: Ebenezer Daniel; Cynthia A Toth; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Stuart L Fine; Jiayan Huang; Gui-shuang Ying; Stephanie A Hagstrom; Katrina Winter; Maureen G Maguire Journal: Ophthalmology Date: 2013-12-04 Impact factor: 12.079
Authors: Stephanie A Hagstrom; Gui-Shuang Ying; Gayle J T Pauer; Gwen M Sturgill-Short; Jiayan Huang; David G Callanan; Ivana K Kim; Michael L Klein; Maureen G Maguire; Daniel F Martin Journal: Ophthalmology Date: 2013-01-18 Impact factor: 12.079
Authors: Ammarin Thakkinstian; Mark McEvoy; Usha Chakravarthy; Subhabrata Chakrabarti; Gareth J McKay; Euijung Ryu; Giuliana Silvestri; Inderjeet Kaur; Peter Francis; Takeshi Iwata; Masakazu Akahori; Astrid Arning; Albert O Edwards; Johanna M Seddon; John Attia Journal: Am J Epidemiol Date: 2012-08-05 Impact factor: 4.897
Authors: Nicolas Leveziel; Nathalie Puche; Florence Richard; John E A Somner; Jennyfer Zerbib; Sylvie Bastuji-Garin; Salomon Y Cohen; Jean-François Korobelnik; José Sahel; Gisèle Soubrane; Pascale Benlian; Eric H Souied Journal: Invest Ophthalmol Vis Sci Date: 2009-12-30 Impact factor: 4.799
Authors: Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin Journal: Ophthalmology Date: 2013-09-29 Impact factor: 12.079
Authors: Milam A Brantley; Sean L Edelstein; Jennifer M King; Rajendra S Apte; Steven M Kymes; Alan Shiels Journal: Am J Ophthalmol Date: 2007-07-12 Impact factor: 5.258
Authors: Milam A Brantley; Amy M Fang; Jennifer M King; Asheesh Tewari; Steven M Kymes; Alan Shiels Journal: Ophthalmology Date: 2007-12 Impact factor: 12.079
Authors: Delu Song; Gui-Shuang Ying; Joshua L Dunaief; Rupak Bhuyan; Yafeng Li; Maureen G Maguire; Juan E Grunwald; Ebenezer Daniel; Stephanie Hagstrom; Daniel F Martin Journal: Retina Date: 2019-10 Impact factor: 4.256
Authors: Maria Cohen; Ashley J Lamparello; Lukas Schimunek; Fayten El-Dehaibi; Rami A Namas; Yan Xu; A Murat Kaynar; Timothy R Billiar; Yoram Vodovotz Journal: Shock Date: 2020-03 Impact factor: 3.533
Authors: Leah A Owen; Akbar Shakoor; Denise J Morgan; Andre A Hejazi; M Wade McEntire; Jared J Brown; Lindsay A Farrer; Ivana Kim; Albert Vitale; Margaret M DeAngelis Journal: Invest Ophthalmol Vis Sci Date: 2019-03-01 Impact factor: 4.799
Authors: Johanna M Seddon; James P Dossett; Rafael Widjajahakim; Bernard Rosner Journal: Invest Ophthalmol Vis Sci Date: 2019-10-01 Impact factor: 4.799